Glycoselect Investment opportunity

GlycoSeLect opens raising round for Irish investors

Dublin- GlycoSeLect has opened a private equity raising round, targeted at Irish tax resident investors.

Investors in the round may be able to avail of the Irish Revenue Commissioners’ Employment & Investment Incentive Scheme (EIIS) allowing them to obtain income tax relief on investments in qualifying Small and Medium Enterprises (SMEs).

The Irish government, through Enterprise Ireland and its other agencies, has been very supportive of companies during the COVID-19 pandemic. This finance round will facilitate further investment and grants to develop our RPL technology in biopharmaceutical manufacturing, especially vaccine and cancer immunotherapy applications.

For more information on this investment opportunity, please contact our CEO, Robert Dunne, by email robert.dunne@glycoselect.com or at GlycoSeLect Ltd phone number 01 2544164.

About GlycoSelect Ltd

GlycoSeLect Ltd is an early-stage biotechnology company developing proprietary innovative and cost-efficient solutions for the analysis, characterisation and purification of pharmaceutical products. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; proteins that enable the more efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect established a UK based subsidiary in 2015 to support further development, provide wider geographic reach and drive commercialisation.

More Stories

Menu